Evidence map›Paper›PMID 36243698›Full record

Trial reportBMC public health2022

Use of mobile data collection systems within large-scale epidemiological field trials: findings and lessons-learned from a vector control trial in Iquitos, Peru.

William H Elson, Anna B Kawiecki, Marisa A P Donnelly, Arnold O Noriega, Jody K Simpson, Din Syafruddin, Ismail Ekoprayitno Rozi, Neil F Lobo, Christopher M Barker, Thomas W Scott and 2 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Public Health Perspectives on IntegratingTropical medicine and infectious disease · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

William H Elson *University of California Davis, Davis, CA, USA.
Anna B Kawiecki *University of California Davis, Davis, CA, USA. akawiecki@ucdavis.edu.ORCID 0000-0002-0499-2612
Marisa A P DonnellyUniversity of California Davis, Davis, CA, USA.
Arnold O NoriegaUniversity of California Davis, Davis, CA, USA.
Jody K SimpsonUniversity of California Davis, Davis, CA, USA.
Din SyafruddinEijkman Institute for Molecular Biology, Jakarta, Indonesia.
Ismail Ekoprayitno RoziEijkman Institute for Molecular Biology, Jakarta, Indonesia.
Neil F LoboDepartment of Biological Sciences, Eck Institute for Global Health, Notre Dame, IND, USA.
Christopher M BarkerUniversity of California Davis, Davis, CA, USA.
Thomas W ScottUniversity of California Davis, Davis, CA, USA.
Nicole L Achee *Department of Biological Sciences, Eck Institute for Global Health, Notre Dame, IND, USA.
Amy C Morrison *University of California Davis, Davis, CA, USA.

Funding

Surveillance Core (B)P01AI098670 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MORRISON, AMY CELESTE · 2014 to 2018
$7.9M
NIAID NIH HHS P01 AI098670
6 · The paper itself

Abstract

Vector-borne diseases are among the most burdensome infectious diseases worldwide with high burden to health systems in developing regions in the tropics. For many of these diseases, vector control to reduce human biting rates or arthropod populations remains the primary strategy for prevention. New vector control interventions intended to be marketed through public health channels must be assessed by the World Health Organization for public health value using data generated from large-scale trials integrating epidemiological endpoints of human health impact. Such phase III trials typically follow large numbers of study subjects to meet necessary power requirements for detecting significant differences between treatment arms, thereby generating substantive and complex datasets. Data is often gathered directly in the field, in resource-poor settings, leading to challenges in efficient data reporting and/or quality assurance. With advancing technology, mobile data collection (MDC) systems have been implemented in many studies to overcome these challenges. Here we describe the development and implementation of a MDC system during a randomized-cluster, placebo-controlled clinical trial evaluating the protective efficacy of a spatial repellent intervention in reducing human infection with Aedes-borne viruses (ABV) in the urban setting of Iquitos, Peru, as well as the data management system that supported it. We discuss the benefits, remaining capacity gaps and the key lessons learned from using a MDC system in this context in detail.

Indexed as

AedesDengueAnimalsData CollectionHumansMosquito ControlMosquito VectorsPeruResearch DesignAedes aegyptiClinical trialCommCareData monitoringData qualityDengueMobile data collectionSpatial repellentVector control

Identifiers

PMID36243698
PMCPMC9571464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.